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Cancer is a set of diseases that exhibit not only genetic mutations but also a profoundly 
distorted epigenetic landscape. Over the last two decades, great advances have been 
made in identifying these alterations and their importance in the initiation and 
progression of cancer. Epigenetic changes can be seen from the very early stages in 
tumorigenesis and dysregulation of the epigenome has an increasingly acknowledged 
pathogenic role. Epigenomic twin studies have great potential to contribute to 
our understanding of complex diseases, such as cancer. This is because the use of 
monozygotic twins discordant for cancer enables epigenetic variation analysis without 
the confounding influence of the constitutive genetic background, age or cohort 
effects. It therefore allows the identification of susceptibility loci that may be sensitive 
to modification by the environment. These studies into cancer etiology will potentially 
lead to robust epigenetic markers for the detection and risk assessment of cancer.
Keywords:  cancer • discordant monozygotic twins • DNA methylation • epigenetics 
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Over the last two decades, great advances 
have been made in our understanding of 
the pathogenesis of cancer. Disease develop-
ment is acknowledged as a multistep process, 
whereby the cancer cell acquires new bio-
logical capabilities that enable tumor growth 
and metastatic dissemination. These include 
sustaining proliferative signaling, evad-
ing growth suppressors, resisting cell death, 
enabling replicative immortality, induc-
ing angiogenesis, and activating invasion 
and metastatic pathways [1,2]. These cellular 
adaptations can be driven through genetic 
mutations, and critical cancer-related genes 
have been identified by the co-segregation 
of mutations in families with rare heredi-
tary cancer syndromes [3–5]. However, it is 
also well known from epidemiological stud-
ies that certain environmental factors have a 
strong influence on cancer risk, for example 
tobacco smoking and UV sunlight exposure. 
In order to quantify this nongenetic effect, 
the unique power of human twin studies has 
been fundamental [6].
These classic twin studies have greatly 
contributed to our knowledge of complex 
diseases as they allow the separate contribu-
tion of genetic and environmental factors to 
be estimated. Human identical, or mono-
zygotic (MZ), twins account for only one in 
approximately 250 pregnancies worldwide. 
These MZ twins originate from an aberrant 
separation of two or more daughter cells of 
a single fertilized ovum and thus share an 
identical genome sequence. The timing of 
this separation can occur at a developmental 
stage as late as 14 days after fertilization [7]. 
Nonidentical, or dizygotic (DZ), twins on 
the other hand, originate when two ova are 
present that are independently fertilized and 
therefore are as genetically similar as normal 
siblings sharing, on average, 50% of segregat-
ing DNA sequence variation [8]. The division 
of the zygote leading to MZ twins is generally 
viewed as a random process and not heritable, 
although some clustering is seen in a few fam-
ilies [9]. MZ twins are extremely similar due 
to not only their shared genetic code (‘virtual 
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clones’), but also due to their shared early environment. 
By contrast, DZ twins share most of these environmen-
tal factors, but with a comparatively much-reduced 
genetic component.
Detailed examination of these MZ individuals has 
revealed that they have surprisingly high rates of dis-
ease discordance for many common disorders, includ-
ing metabolic disease, autoimmune disease, and cancer 
[10–13]. This difference in disease occurrence between 
MZ twins is typically interpreted as the result of envi-
ronmental factors, although this component will also 
include stochastic effects [14]. What should be kept in 
mind is that in order to establish the most accurate dis-
ease concordance rates, a sufficient observation window 
is required. This is to diagnose correctly whether an 
individual is healthy or affected, and should be as near 
to the entire life span as possible. This is particularly the 
case for predominately late-onset diseases, such as can-
cer. The concordance rate, for example, was observed 
to be below 0.10 in MZ twins with cancer, by a large 
twin multi-country analysis. In this study, the youngest 
cohorts diagnosed with prostate, colorectal and breast 
cancer, were followed up until 70, 63 and 56 years, 
respectively [15]. For these, the most common types of 
cancer, the contribution of the nongenetic component 
was estimated to be 60–70% (Table 1). The precise 
mechanism of how these external factors contribute 
to the development of cancer is unknown; however, a 
prime candidate is via changes in the epigenome [16]. 
Compared with a generally static DNA sequence 
throughout life, the epigenome represents a dynamic 
landscape that undergoes specific changes at various 
stages in development [17,18], as well as modification 
at identified aging-related loci and random ‘drift’ 
throughout the lifetime of an individual [19–22]. This 
change over time is believed to be not only due to 
intrinsic factors, but also environmental effects [23]. It 
has been shown that the epigenome can be influenced 
by prenatal and early postnatal environmental influ-
ences, such as maternal behavior in rodents [24] and 
maternal diet in humans [25,26]. Therefore epigenetic 
epidemiology may have the potential to link changes 
in gene activity directly or in combination with genetic 
risk factors, influencing penetrance and expressivity, 
with environmental conditions and exposures. Due 
to its essential role in gene expression, abnormalities 
in the epigenome have been proposed to contribute 
to the spectrum of complex diseases [27] and especially 
to human cancers [28,29]. Furthermore, the high level 
of genetic mutations recently identified in genes that 
direct the epigenome also points towards this level of 
regulation as being a significant pathogenic player in 
cancer [30,31], for example, ARID1A in ovarian clear cell 
carcinoma [32].
In this article, we will discuss primarily the patterns 
of the most well-studied epigenomic mark, DNA meth-
ylation, in healthy and cancer subjects in the general 
population, the contribution of epigenetic twin studies 
in complex diseases, and finally the use of these studies 
in cancer research.
DNA methylome in healthy & cancer tissues
In the past few years, the ability to characterize the 
epigenome in both normal and cancer tissues has been 
Table 1. The concordance rate and effects of heritable and nonshared environmental factors in 
cancer at various sites.
Site or type MZ concordance rate 
(men/women)
Heritable factors 
(95% CI)
Nonshared environmental 
factors (95% CI)
Stomach 0.08/0.10 0.28 (0.00–0.51) 0.62 (0.49–0.76)
Colorectum† 0.09/0.16 0.35 (0.10–0.48) 0.60 (0.52–0.70)
Pancreas 0.06/0.03 0.36 (0.00–0.53) 0.64 (0.47–0.86)
Lung 0.11/0.09 0.26 (0.00–0.49) 0.62 (0.51–0.73)
Breast† 0.00/0.14 0.27 (0.04–0.41) 0.67 (0.59–0.76)
Cervix –/0.02 0.00 (0.00–0.42) 0.80 (0.57–0.97)
Uterus –/0.02 0.00 (0.00–0.35) 0.82 (0.64–0.98)
Ovary –/0.05 0.22 (0.00–0.41) 0.78 (0.59-0.99)
Prostate† 0.21/– 0.42 (0.29–0.50) 0.58 (0.50–0.67)
Bladder 0.06/0.00 0.31 (0.00–0.45) 0.69 (0.53–0.86)
Leukemia 0.07/0.00 0.21 (0.00–0.54) 0.66 (0.45–0.88)
†Statistical significant effects of heritable factors. 
–: Not applicable; MZ: Monozygotic. 
Adapted with permission from [15].
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revolutionized and made genome-wide analysis pos-
sible. The complexity of tumorigenesis involves both 
genetic and epigenetic changes that lead to abnormal 
gene expression patterns regulating the tumor pheno-
type [33,34]. In the progression of cancer development, 
cells acquire new characteristics that overcome normal 
regulation of differentiation, proliferation and cell 
death. These changes in the transcriptome include 
processes such as activation of oncogenes and deactiva-
tion of tumor suppressor genes [2]. Epigenetic changes, 
such as DNA methylation, can be seen in early neo-
plastic and even in precancerous tissues [35,36]. For 
example, a key early tumor adaptation to frequently 
encountered hypoxic conditions is accompanied by 
epigenomic changes [37,38]. Recent data have shown 
that in cancerous cells, epigenetic changes affect more 
genes than genetic mutations and can often act as 
surrogate modifications to commonly altered cancer 
genes [39]. This further indicates the importance of 
epigenetic alterations in the initiation and progression 
of cancer development. Dysregulation of the epig-
enome is thus a mechanism that enables the cancer 
cell to gain a growth advantage [40].
DNA methylome in healthy tissues
DNA methylation comprises the covalent addition 
of a methyl group to the five-carbon position of the 
cytosine almost exclusively in CpG dinucleotides in 
differentiated cells in the mammalian genome. CpG 
dinucleotides are found at a much lower frequency 
than expected due to the hypermutability of methyl-
ated cytosines, with the majority of these randomly 
dispersed throughout the genome and predominately 
methylated (70–80%) [41]. However, a small propor-
tion of the total genomic CpG dinucleotides (∼7%) 
typically cluster together in specific regions known 
as CpG islands (CGIs), half of which are located at 
established gene promoters, near transcription start 
sites and first exons. The remainder are evenly split 
between intragenic and intergenic regions of the 
genome [42], with the former being potential alter-
nate isoform promoters [43,44]. Approximately 70% 
of genes in the human genome have CGIs in their 
promoter region and the majority of these promoter 
CGIs remain unmethylated [45]. However, methyla-
tion in these regions commonly correlates with tran-
scriptional repression and this has been established in 
genomic imprinting, X inactivation and suppression 
of transposable elements [46]. Inversely, high levels of 
DNA methylation within the gene body region is gen-
erally associated with higher levels of transcriptional 
activation [47–49]. Aberrant DNA methylation pat-
terns, both global trends and promoter specific, are a 
hallmark of cancer [50].
DNA methylome in cancer
Global hypomethylation
The first epigenetic alteration identified in cancer was 
the global reduction of methylation levels in cancer 
patients compared with healthy subjects in primary 
human tumor tissue [51,52]. Recent studies have revealed 
that the substantial loss of methylation involves large 
hypomethylated blocks covering more than half of the 
genome at consistent locations [28,53]. These are primar-
ily located in partially methylated domains comprising 
a significant number of developmental genes. Surpris-
ingly, hypomethylation of the blocks is accompanied by 
the formation of repressive chromatin marks associated 
with lamin nuclear regions and silencing of the genes 
within these regions [54]. Neighboring these hypometh-
ylated blocks are focal hypermethylation regions at cer-
tain promoter CGIs. Further indicating the complexity 
of integrating expression with methylation, these were 
associated with gene activation and are termed long-
range epigenetic activation regions [34]. Even though 
only a minority of CGI promoters are methylated in 
normal somatic cells, there are a number of oncogenes 
identified that show a loss of methylation at their pro-
moters and associated activation of gene expression in 
tumor tissues. These include key genes in tumorigen-
esis such as RRAS [55], MAGE1 [56], XAGE1A [57] and 
MASPIN [58]. Overall, the global loss of methylation 
is a key abnormality in cancer cells and is associated 
with repressive chromatin marks and silencing of genes 
within these regions. Together with neighboring long-
range epigenetic activation regions, it highlights the 
importance of chromatin boundaries in healthy cells.
Promoter-specific CGI hypermethylation
The most extensively studied modification is the gain 
of methylation at normally unmethylated gene pro-
moter CGIs, which are classically associated with tran-
scriptional repression [29,59,60]. Large numbers of genes 
have been found to be hypermethylated in different 
types of cancer tissues at various stages of tumorigen-
esis. This can affect at least 5% of all promoter CGIs 
that are normally unmethylated in somatic cells [61]. 
The hypermethylation at individual genes is generally 
associated with stable gene silencing and can be tumor-
type specific [62]. Many tumor suppressor genes have 
been identified in the last two decades that are hyper-
methylated and generally repressed in multiple types 
of cancer including RB1 [63], CDKN2A [64], MLH1 
[65], VHL [66] and BRCA1 [67]. More recently, promoter 
hypermethylation was found to disrupt miRNA path-
ways associated with upregulated target oncogenes, 
such as BCL6 [68]. Promoter-specific hypermethylation 
is found in significant cellular pathways, such as DNA 
repair, cell cycle control, apoptosis and metastasis [69].
302 Epigenomics (2014) 6(3) future science group
Review    Roos, Spector & Bell
Non-CGI methylation variation
Methylation changes in cancer are not restricted 
to promoter-specific CGIs. In 2009, a study by 
Irizarry et al. showed that the CGI ‘shores’, the regions 
approximately 2 kb upstream and downstream of the 
island, undergo significant methylation changes and 
also contribute to gene dysregulation. In fact, these dif-
ferentially methylation regions (DMRs) occurred more 
frequently here than within the CGIs themselves and 
were associated with not only cancer-specific, but also 
tissue-specific and reprogramming-specific changes 
[70,71]. In addition, hypomethylation was also identified 
at shores near cell cycle-related genes that were associ-
ated with overexpression in cancer cells [28]. This high-
lighted that in cancer, the loss of the strict boundary 
in methylation change occurring at the CGI edges is 
crucial. The importance of CGI shore regions has also 
been shown during the course of development where 
they exhibit a tidal-like change with variable narrow-
ing of the hypomethylated region in a lineage-specific 
fashion during the process of cell differentiation [72]. 
DMRs within these regions have been found to define 
tissue specificity more strongly than within the CGI 
themselves [73]. Furthermore, gene distal moderately 
concentrated CpG regions, termed low methylation 
regions [74] or intergenic hypomethylation regions [75] 
indicate potential tissue-specific enhancer loci. These 
intergenic hypomethylation regions were found to be 
more predictive of nearby gene expression than the 
promoter state itself [75].
Recent advances have further indicated the com-
plexity of interpreting the epigenome and that genome-
wide methylation data are required to fully explore and 
unravel the complete significance of these changes. 
Analysis of the methylation state of repetitive elements 
is also required due to their latent regulatory potential 
and paired-ended sequencing data enables improved 
access into these genome regions [76]. DMRs can be 
further delineated for functionality by overlap with 
genomic segmentation data, derived from coalesced 
chromatin signals [77], as well as transcription fac-
tor-binding motifs, such as for CTCF [78] and other 
complex interactions [79].
Twin model in epigenetics
MZ twins provide the unique opportunity to investi-
gate the contribution of epigenetic variation between 
genetically identical individuals in complex diseases. 
They are ideally matched for genetic factors, age, 
cohort effects, maternal influences and common envi-
ronment [80]. The dynamic nature of the epigenome 
can lead to discordance in these markers between MZ 
twins. Studies have shown that gene expression pro-
files in MZ twins already display differences at birth, 
highlighting the effect of the in utero environment 
[81,82]. Furthermore, developmental changes continue 
to occur, within, for example, the immune system 
where differences have been identified longitudinally 
until at least 5 years of age [83]. Epigenetic studies in 
twins give valuable insight into the heritability and 
stability of the epigenome and the epigenetic variation 
associated with disease discordance [80].
Heritability of the epigenome
Several studies have examined DNA methylation pro-
files between MZ and DZ pairs to identify the extent of 
epigenetic variation in genetically identical individuals 
and the heritability of the epigenome. Heritability is an 
estimate of the proportion of phenotypic variance that 
can be attributed to genetic effects in a population. 
The classic twin method of estimating the heritability 
compares MZ and DZ concordance rates or intraclass 
correlations. This method can be used to estimate the 
proportion of epigenetic (i.e., DNA methylation) vari-
ance that can be attributed to genetic effects per single 
locus [84]. Early array studies investigated methylation 
profiles between MZ twin pairs [85] and estimated heri-
tability at multiple genomic locations across different 
tissues to be approximately 15% [85,86]. These findings 
revealed that MZ twins have very similar epigenetic 
profiles. However, a greater discordance was observed 
between older MZ twin pairs [20,85].
More recent analyses have estimated heritability of 
the methylome on a genome-wide scale using DNA 
methylation arrays such as the Illumina Infinium 
Human Methylation 27 Beadchip (Illumina 27k) 
comprising approximately 27,000 probes and the Illu-
mina Infinium Human Methylation 450 (Illumina 
450k) comprising approximately 480,000 probes. 
First, a study by Bell et al. examined heritability using 
the Illumina 27k comparing methylation rates within 
33 MZ and 43 DZ twin pairs. They estimated a mean 
genome-wide heritability of 18% across 26,690 CpG 
sites [87]. Subsequently, Grundberg et al. performed a 
large-scale heritability analysis with the Illumina 450k 
array, including 97 MZ and 162 DZ twins and esti-
mated the heritability for 344,092 methylation sites. 
In concordance with previous estimates, the overall 
heritability was estimated to be 19% [88].
DNA methylation profiles have also been shown 
to diverge over time within MZ twin pairs [85,86]. 
Recently, DNA methylation levels were assessed both 
globally (LINE1) and at nine candidate gene loci for 
common diseases for similarity in 230 MZ twin pairs 
aged 19–89 years old [19]. The results were similar to 
those of earlier studies, in that older pairs were found 
to have double the discordance of younger twins. 
A longitudinal approach, albeit in five specific loci, 
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identified a similar pattern of greater within-pair dis-
cordance after 10 years, as well as individual-specific 
methylation changes.
Together these findings confirm that the DNA 
methylation profile is heritable to a large extent, but 
does change over the lifetime of an individual, influ-
enced by genetic variation, stochastic factors, and the 
environment.
Discordant MZ twin model in complex disease
The use of the discordant MZ twin design should elu-
cidate genes that are sensitive to environmental factors 
in complex diseases. As they are an ultimately matched 
case–control study, they will be superior to population-
based case–control approaches in detecting changes 
in the epigenome without significant confounding 
by genetic, aging, and cohort factors [84]. Over the 
past two decades, a number of studies have identified 
methylation differences in MZ twins associated with 
multiple diseases and phenotypes. The earliest studies 
were characterized by limited twin pair numbers and a 
focus only on specific candidate gene promoters. A first 
report found that the DRD2 gene in lymphocytes had 
greater methylation differences in the discordant than 
the concordant pair in association with schizophrenia 
[89]. Other studies identified methylation differences 
in single gene promoters in MZ twins discordant for 
birth weight using buccal swabs and caudal duplication 
anomaly in peripheral blood mononuclear cells [90,91]. 
One of the better-known examples of methylation dif-
ferences is the loss of imprinting at the KCNQ1OT1 
gene, identified in skin fibroblasts, of the affected MZ 
twin of a pair discordant for Beckwith-Wiedemann 
syndrome [92].
In the last few years, the advent in high-throughput 
DNA methylation microarrays have given rise to a 
number of epigenome-wide association studies in dis-
cordant MZ twins. These studies highlight the value 
of the discordant MZ twin design by unraveling new 
candidate genes for diseases using whole blood samples 
or blood-derived cells, such as bipolar disorder [93], sys-
temic lupus erythematous [94], scleroderma [95], autism 
[96,97] and schizophrenia [98]. Although these stud-
ies have small numbers of discordant MZ twin pairs 
and will require replication in order to be confirmed, 
they have revealed an interesting new view on DNA 
methylation changes largely independent of genome 
sequence variation in a large number of regions across 
the genome.
In contrast to previous discordant MZ twin stud-
ies, a study on pain sensitivity in 25 discordant MZ 
twin pairs and 50 unrelated subjects assayed genome-
wide DNA methylation using methylated DNA 
immunoprecipitation followed by second-generation 
sequencing. In a case–control approach, nine genome-
wide significant pain DMRs were identified that were 
subsequently validated by deep bisulfite pyrosequenc-
ing, as well as by Illumina 450k array when CpG 
probes were available in or near the DMR sites (52% 
of the top 100 pain DMRs). Using a pure discordant 
MZ twin pair design, the results included several of 
the top 100 ranked pain DMRs from the case–control 
approach. These distinguished regions in the genome 
for pain sensitivity that were nongenetic and may be 
due to environmental effects [99].
Now with increased availability of base-resolution 
whole-genome bisulfite sequencing data, meta-anal-
yses have started to determine where in the genome 
the most variable or ‘dynamic’ DNA methylation 
regions are located [41]. These results indicate that the 
current DNA methylation arrays and even techniques 
such as reduced-representation bisulfite sequencing are 
poorly capturing this dynamic methylome (27k: 0.7%; 
450k: 8.9%; reduced-representation bisulfite: 11.5%). 
Whole-genome bisulfite sequencing remains the gold 
standard, but is extremely costly and inefficient with 
approximately 70–80% of the reads generated hav-
ing either no CpGs present or only fully methylated 
nonvariant CpGs [41].
The epigenomic landscape varies significantly across 
different tissue types and is a prerequisite consideration 
when designing any type of epigenetic study. The cell-
type that is most relevant to disease will potentially 
exhibit cell-specific pathogenic epigenetic changes. 
Unfortunately, some disease-relevant tissues are not 
easily available and can only be procured via post-
mortem material or invasive methods. Many studies 
have therefore been performed using peripheral tis-
sues, such as whole blood, as an alternative to try to 
identify surrogate epigenetic changes associated with 
disease. Any findings arising should therefore be cross-
validated in disease-related tissue. Nevertheless, sev-
eral studies have shown evidence that some epigenetic 
changes in blood were similar to changes seen across 
different tissues [100,101].
The rise of discordant MZ twin epigenome-wide 
association studies has the potential to identify genes 
and loci sensitive to the environment that are associ-
ated with the range of complex diseases, but there is an 
increasing need for high-resolution studies, with suf-
ficient numbers of samples, and replication/validation 
of results to yield convincing results.
Discordant MZ twin studies in cancer
At present, two studies have focused solely on DNA 
methylation differences in cancer discordant MZ twins. 
Apart from familial cancers (5–10%), in which highly 
penetrant genetic mutations play a major role [102], the 
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contribution of common inherited genetic factors iden-
tified in sporadic cancers is still moderate. The recent 
surge of genome-wide association studies since 2007 
have identified multiple common genetic variants in 
different cancer phenotypes, although they individu-
ally have relatively modest effect sizes (∼1.1–1.3 rela-
tive risk), and even in combination can only account 
for a total of approximately 10% of the heritability 
[14]. As the DNA methylome can be, to a large extent, 
heritable due to the influence of CpG-SNPs and the 
existence of various methylation quantitative trait loci, 
MZ twins can help to unravel the potential environ-
mental component of the epigenetic mutations seen in 
cancer (Figure 1).
Galetzka et al. described one MZ twin pair discor-
dant for childhood leukemia and secondary thyroid 
cancer [103]. They assessed DNA methylation at the 
promoter sites of six tumor suppressor genes includ-
ing the well-studied BRCA1 gene in skin tissue. The 
BRCA1 protein is significantly involved in the main-
tenance of genome integrity and mutations at the 
BRCA1 gene causes most hereditary breast and ovarian 
cancers [104]. At the BRCA1 promoter, an increase in 
methylation was shown constitutively in the affected 
twin, when compared with her healthy co-twin. Addi-
tionally, basal expression levels of BRCA1 protein were 
lower in the affected twin. They proposed that the dif-
ference in DNA methylation may have occurred dur-
ing early embryogenesis, after the blastocyst fission and 
predisposes the individual to tumor development later 
in life [103]. It is an interesting finding, however limited 
as they could only study one MZ pair and six tumor 
suppressor genes. Hypermethylation of the BRCA1 
promoter has been previously identified in 10–15% of 
sporadic nonfamilial breast cancer [105,106] and, thus, 
strongly supports the hypothesis that epigenetic, as 
well as genetic modifications, contribute to cancer [107].
The second study by Heyn et al. assessed DNA meth-
ylation differences in whole blood on an epigenome-
wide scale in 15 MZ twin pairs discordant for breast 
cancer [108]. The Illumina 450k was used to uncover 
key genes involved in the development of cancer. They 
detected 403 differentially methylated positions, of 
which the vast majority of loci were hypomethylated 
in the affected twin. Interestingly, 27% were located 
in CGI shore regions. Of these results, 14 CpG sites 
were examined in a validation cohort of 21 discordant 
MZ twin pairs and the gene DOK7, was shown to be 
hypermethylated in the cancer-affected twins. This 
was consistent across four neighboring CpG sites, 
forming a cancer-related DMR. The increased meth-
ylation was also shown in a subset of four whole blood 
samples taken 4–5 years prior to diagnosis and was 
confirmed in primary tumor samples and cancer cell 
lines, suggesting that DOK7 and similar genes could 
be promising epigenetic blood biomarkers for early 
breast cancer diagnosis [108].
Future perspective
The power to detect methylation differences in cancer 
using the discordant MZ design will depend on many 
factors, other than improving sample size. Most studies 
use whole blood and this analysis contains a mixture of 
the constituent blood subtypes’ epigenomes and, thus, 
is a composite representation that needs to be taken 
into account. The sensitivity of DNA methylome anal-
ysis means cell-type deconvolution is now possible, 
and will improve with increasingly higher resolution 
data [109], although subtle cell-type changes themselves 
could be pathognomonic. Exposure-specific non-
shared environmental risk factors may also be present 
across cell types, but only be involved in pathogenesis 
in particular cell types in which the disease-related 
gene is expressed [110], thus further adding a surrogate 
potential of blood methylation findings.
As twin cohorts are often longitudinal, they contain 
a wealth of information, making it possible to have 
DNA methylation samples even prior to diagnosis. The 
opportunity to study the predisease methylation state 
in MZ twins could identify methylation differences 
that provide the ‘first hit’, making individuals more 
susceptible to the development of cancer and therefore 
serve as a predictive biomarker. Using nonprimary tis-
sue samples taken after cancer diagnosis could iden-
tify markers that are related to systemic epigenetic 
events that reflect the consequence of this disease or 
treatment.
One of the major limitations for a cancer discordant 
MZ twin design is the collection of samples. Although 
there are over 60 twin registries worldwide [111], few 
except for the larger European collections are focused 
on cancer and have DNA saved either from blood or 
tissue. Furthermore, substantial numbers are needed 
for a powerful discovery set and therefore pooling 
of resources is required. TwinsUK, together with six 
other twin registries from Europe and Australia, are 
involved in the set up of a consortium of this nature 
(EUrodiscotwin), with the purpose of collecting infor-
mative discordant MZ twin pairs. This, in combina-
tion with replication in vast available case–control data, 
could make a major impact in advancing knowledge 
for many types of cancers.
Genome-wide epigenetic-modifying agents are 
already licensed for some hematological cancers [29] 
and trialed in others [112]; however, the future possi-
bilities of targeted ‘epidrugs’, due to the malleability of 
epigenetic changes, could be considerable. In the com-
ing years, these modifications will require functional 
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assessment through rapidly emerging sequence-specific 
technologies, such as TALENs [113] and CRISPR [114]. 
Thus, if through the exceptional biology of MZ twins 
convincing variation can be first identified, these 
epigenetic changes have the potential to move from 
markers of disease to targets of future therapeutics.
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Executive summary
Epigenome
•	 The epigenome has a crucial role in the regulation of gene expression.
•	 It represents a dynamic landscape that possesses a degree of plasticity to react to the environment.
•	 It has the potential to link gene activity with environmental conditions and exposures.
DNA methylome in cancer
•	 Cancerous cells have a profoundly distorted epigenetic landscape.
•	 Recent data have shown that, in cancerous cells, more genes are affected by epigenetic changes than genetic 
changes.
Discordant monozygotic twin studies in cancer
•	 The discordant monozygotic design offers the unique opportunity to study epigenetic variation without 
significant confounding by genetic factors.
•	 They have the potential to quantify environmental risk factors through the measurement of epigenetic 
modifications.
•	 Epigenetic studies in cancer discordant monozygotic twins will enable novel insights in cancer etiology, 
improving prediction, diagnosis and prognosis.
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